ClinicalTrials.gg

Program

comekibart

Also written as “MG-K10”, “MG-K10 Injection” and “MG-K10 Injection (Humanized Monoclonal Antibody)”.

Its studies are mostly in Nasal Polyps · Chronic Urticaria · Dermatitis, Atopic, led by Shanghai Mabgeek Biotech..

Furthest: phase 3, since Apr 13, 20263 company-led studies, 3 open or runningNext primary completion: Jan 5, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Mabgeek Biotech.33 open or runningphase 3since Apr 13, 2026Apr 13, 2026Jan 5, 2027phase 3 · NCT07540442

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2026First study: phase 3 study in Dermatitis, AtopicFirst studyNCT07540442 · 180 planned · China
  2. Sep 14, 2026Phase 2 study in Chronic UrticariaNCT07838727 · 60 planned
  3. Oct 14, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07903194 · 210 planned

Ahead

  1. Jan 5, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07540442
  2. May 7, 2027Primary completion: phase 2 study in Chronic UrticariaNCT07838727
  3. Dec 21, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07903194

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903194Chronic Rhinosinusitis With Nasal Polyps3Not yet recruitingDec 21, 2027210
NCT07838727Chronic Urticaria2Not yet recruitingMay 7, 202760
NCT07540442Dermatitis, Atopic · China3Not yet recruitingJan 5, 2027180

How it is read

Names in the registry

  • “MG-K10”, 1 entry
  • “MG-K10 Injection”, 1 entry
  • “MG-K10 Injection (Humanized Monoclonal Antibody)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.